SCHEMBL1944797

SCHEMBL1944797

COCCNc1nn2cc(-c3cccnc3)nc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 6/20 0.44
SMN1; SMN2 Q16637 6/20 0.43
TP53 P04637 4/20 0.43
MAPT P10636 3/20 0.43
CYP1A2 P05177 3/20 0.43
CYP3A4 P08684 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
HIF1A Q16665 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
RAB9A P51151 5/20 0.42
HPGD P15428 1/20 0.42
NPC1 O15118 4/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1947874 0.88 F2RL3 (0.57) F2RL3SMN1; SMN2TP53MAPTCYP1A2
SCHEMBL1945098 0.86 GBA1 (0.48) F2RL3SMN1; SMN2TP53MAPTHSD17B10
SCHEMBL1944509 0.83 FYN (0.45) SMN1; SMN2TP53MAPTHSD17B10ALDH1A1
SCHEMBL1945450 0.83 FYN (0.52) SMN1; SMN2TP53MAPTCYP1A2CYP3A4
SCHEMBL1946042 0.83 FYN (0.47) F2RL3SMN1; SMN2TP53MAPTALDH1A1
SCHEMBL1948278 0.82 MKNK1 (0.49) F2RL3SMN1; SMN2TP53MAPTHSD17B10
SCHEMBL15603263 0.82 FYN (0.46) F2RL3SMN1; SMN2TP53MAPTCYP1A2
SCHEMBL1946947 0.82 F2RL3 (0.60) F2RL3SMN1; SMN2TP53MAPTHSD17B10
SCHEMBL1947772 0.82 MAPT (0.52) F2RL3SMN1; SMN2TP53MAPTCYP1A2
SCHEMBL1944433 0.82 F2RL3 (0.62) F2RL3SMN1; SMN2TP53MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R F2RL3 1121/4885SMN1; SMN2 4370/4885TP53 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.